Trial Profile
A trial of intravitreal ranibizumab for the treatment of patients with acute central serous chorioretinopathy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Central serous chorioretinopathy
- Focus Therapeutic Use
- 03 Dec 2015 New trial record